Using a simulation-based drug discovery platform, Turbine is dramatically reshaping drug discovery and development, explains CEO and co-founder Szabolcs Nagy, a 2021 Rising Leader.
Back To Rising Leaders Gallery
Even though the industry’s knowledge of biology is expanding, drug development timelines and costs continue to increase while the chances of clinical success rates decrease. The average cost to bring a drug to market is in the billions and the competition is fierce. It is critical for pharma companies to embrace drug development strategies that can quickly identify novel targets. Identification, failure and success must now move at a rapid pace
Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.
The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.
Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.
Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.
